Avonex News and Research

RSS
Avonex is a form of a protein called beta interferon that occurs naturally in the body. It is used to treat relapsing forms of multiple sclerosis. It will not cure your MS but may decrease the number of flare-ups of the disease and slow the occurrence of some of the physical disability that is common in people with MS. MS is a life-long disease that affects your nervous system by destroying the protective covering (myelin) that surrounds your nerve fibers.
Zinbryta gets FDA approval for treating adults with relapsing forms of MS

Zinbryta gets FDA approval for treating adults with relapsing forms of MS

New study shows 'alarming rise' in costs of MS drugs over last 20 years

New study shows 'alarming rise' in costs of MS drugs over last 20 years

Dimethyl fumarate offers no added benefits for adults with RRMS

Dimethyl fumarate offers no added benefits for adults with RRMS

Biogen Idec's revenue increases 51% to $2.1 billion in first quarter 2014

Biogen Idec's revenue increases 51% to $2.1 billion in first quarter 2014

Biogen Idec, UCB sign agreements to commercialize treatment of MS and hemophilia in Asia

Biogen Idec, UCB sign agreements to commercialize treatment of MS and hemophilia in Asia

LA BioMed receives grant to study role of serum Vitamin A in people with multiple sclerosis

LA BioMed receives grant to study role of serum Vitamin A in people with multiple sclerosis

New data show positive results from Phase 4 study of Avonex Pen for treatment of RRMS patients

New data show positive results from Phase 4 study of Avonex Pen for treatment of RRMS patients

Biogen Idec Q3 total revenues increase 32% to $1.8 billion

Biogen Idec Q3 total revenues increase 32% to $1.8 billion

Biogen acquires TYSABRI stake from Elan

Biogen acquires TYSABRI stake from Elan

FDA accepts Genzyme’s LEMTRADA sBLA for review

FDA accepts Genzyme’s LEMTRADA sBLA for review

Biogen Idec announces availability of two new AVONEX dosing innovations for MS

Biogen Idec announces availability of two new AVONEX dosing innovations for MS

Biogen Idec first quarter revenues increase 7% to $1.3 billion

Biogen Idec first quarter revenues increase 7% to $1.3 billion

Biogen Idec announces new easier to use injection for multiple sclerosis

Biogen Idec announces new easier to use injection for multiple sclerosis

Biogen Idec receives FDA approval for two separate dosing innovations to treat MS

Biogen Idec receives FDA approval for two separate dosing innovations to treat MS

Biogen Idec 2011 total revenues increase 7% to $5.0 billion

Biogen Idec 2011 total revenues increase 7% to $5.0 billion

Biogen Idec third quarter revenues increase 11% to $1.3 billion

Biogen Idec third quarter revenues increase 11% to $1.3 billion

COPAXONE reduces loss of brain volume in patients with RRMS

COPAXONE reduces loss of brain volume in patients with RRMS

New report on the immunomodulators market outlook to 2016

New report on the immunomodulators market outlook to 2016

Biogen Idec reports revenue of $1.2 billion for second quarter 2011

Biogen Idec reports revenue of $1.2 billion for second quarter 2011

High cost of multiple sclerosis drugs

High cost of multiple sclerosis drugs